Xenetic Biosciences FY2024 net loss $4.0M; cash $6.2M; advancing DNase I to IND

Xenetic Biosciences, Inc.

Net loss ~$4.0M for FY2024; R&D expenses fell 5.9% to $3.3M from $3.5M YoY.
Royalty payments from Takeda sublicense ~$2.5M, relatively flat vs. prior year.
Cash and cash equivalents at year-end ~$6.2M.
Continuing DNase I development toward IND/Phase 1 for pancreatic carcinoma.
Entered Clinical Trial Services Agreement with PeriNess for exploratory studies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.